国内《耐药结核病化学治疗指南(2019年)》与相关共识的特色及要点分析

Characteristics and points analysis of national Guidelines on chemotherapy of drug-resistant tuberculosis(2019)and associated consensus

作者针对国内《耐药结核病化学治疗指南(2019年)》(简称“《指南(2019)》”)与《中国耐多药结核病和利福平耐药结核病治疗专家共识(2019年版)》的异同进行具体分析,并与WHO相关指南进行比对,从药物的分组、抗结核治疗的实施路径、《指南(2019)》的特色与国内耐药结核病治疗研究的发展方向等方面进行阐述,为临床一线医师对指南的理解提供思路。

Authors made analysis on the similarities and differences of Chinese Guidelines on chemotherapy of drug-resistant tuberculosis(2019)(abbreviated as“Guidelines 2019”)and Chinese consensus on multidrug-resistant tuberculosis and rifampin resistant tuberculosis treatment(2019 edition)and compared with WHO guidelines,provided the ideas from the elaboration on drug groups divided,implement approach of anti-TB treatment,the characteristics of Guidelines 2019 and future development direction of national drug-resistant treatment for clinical physicians.